Articles tagged with Drug Studies
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
A sharp increase in colchicine's price led to a 17% drop in its use and worsened disease control in gout patients. Patients turned to alternative medications with potentially different side effects, resulting in increased emergency department visits and specialist consultations.
Researchers identify OmpU protein variants associated with antimicrobial resistance in Vibrio cholerae bacteria. Understanding the evolutionary origins of AMR can inform the development of effective therapeutics against resistant infections.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
A pilot study found that high-dose tadalafil improved metabolic control and reduced hemoglobin A1c levels by 2.50 mmol/mol in patients with well-controlled type 2 diabetes. The treatment also showed increased blood flow, liver values, and metabolism.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
A recent study reveals that many children with attention-deficit/hyperactivity disorder (ADHD) are not receiving adequate treatment. The findings highlight the need for improved communication and access to outpatient mental health care for children with ADHD.
A preclinical study found that suvorexant reduced prescription opioid intake and helped protect against relapse in rats modeling opioid use disorder. The insomnia drug could offer a promising approach for the millions of people affected by OUD.
Researchers developed a biomarker signature test to predict which bladder cancer tumors will respond to immunotherapy, potentially improving survival rates. The study identified three types of responsive tumors and two non-responsive ones, providing insights into potential new treatments.
A new meta-analysis found that clozapine is associated with decreased insomnia and a lower risk of suicide in patients with schizophrenia. The study suggests that clozapine's ability to improve sleep quality may be linked to its reduced suicide risk, and highlights the importance of assessing and treating insomnia in these patients.
A new genetic therapy, BIIB080, has been shown to safely lower levels of the harmful tau protein in patients with Alzheimer's disease. The trial found a greater than 50% reduction in tau protein concentrations after 24 weeks in treatment groups.
A growing number of states have implemented policies to cover outpatient hemodialysis for undocumented immigrants with kidney failure. This expansion may be due to increased awareness of poor outcomes with emergency hemodialysis and advocacy efforts. The move towards covering dialysis in all 50 states is called for by experts, who also...
Research finds diclofenac's high variability in metabolism due to UGT2B17, a little-studied enzyme. The study suggests genetic testing and dose adjustments for specific populations can help minimize side effects.
Researchers have identified a possible way to help break the cycle between sleep disturbances and Alzheimer's disease. A small study found that people who took a sleeping aid experienced a drop in key Alzheimer's proteins.
A Phase I and Phase II clinical trial of the immunotherapy REGN5459 resulted in a 90.5 percent overall response rate among patients with relapsed multiple myeloma. The treatment is reasonably tolerated, with common side effects including cytokine release syndrome.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
A recent study published in the New England Journal of Medicine found that tranexamic acid did not reduce the need for blood transfusions or prevent maternal death in patients with increased risk for excessive bleeding after cesarean delivery. However, patients who received tranexamic acid had less need for additional medical intervent...
Two investigational drugs targeting the renin-angiotensin system were found ineffective in treating severe COVID-19. The study suggests that increasing levels of ANG II may contribute to lung damage and inflammation, but this theory was not supported by the trial results.
A new study found that more than 60% of parents had heard of PrEP, with relatively low levels of knowledge and high intentions to discuss and support their adolescents' PrEP care. The study highlights the importance of educating parents about PrEP to increase self-efficacy and uptake among at-risk populations.
A simulation modeling study finds that involuntary displacement worsens overdose and hospitalizations, decreases treatment initiation, and contributes to deaths. The study projects substantial increases in morbidity and mortality over a 10-year period in cities with such displacements.
Researchers have developed a glycine-based tripeptide that successfully treats nonalcoholic fatty liver disease in non-human primates and mice. The compound, DT-109, reverses fat buildup and prevents scarring by stimulating fatty acid degradation and antioxidant formation.
A study from Indiana University School of Medicine found that people with NAFLD have significantly decreased levels of the liver enzyme CYP2C19, which is important for medication processing. This decrease may lead to slower clearance of certain medications and reduced effectiveness of medicines like antidepressants and clopidogrel.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
Researchers have identified a promising new combination of drugs to treat juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer affecting children. The combination of 5-azacitidine and MEK inhibitor PD0325901 reduced cancerous stem cells and improved blood cell abnormalities.
Researchers from the London School of Hygiene & Tropical Medicine found that intramuscular administration of tranexamic acid (TXA) is safe and quickly reaches therapeutic concentrations in pregnant women. Oral TXA was also well-tolerated but took an hour to reach therapeutic blood concentrations.
A recent clinical study found that an online e-health program helped more people with chronic pain reduce their opioid medications and pain intensity than a control group. The program, called Goalistics Chronic Pain Management, improved pain knowledge, confidence managing pain, and coping skills.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
Researchers found that using monoclonal antibodies within two days of a COVID-19 diagnosis reduced the risk of hospitalization or death by 39% compared to those who did not receive treatment. This finding suggests that early treatment with monoclonal antibodies significantly reduced the severity of COVID-19.
A multi-site NIH study shows that less than 1% of people with opioid use disorder experience withdrawal when starting buprenorphine in the emergency department. The findings provide strong evidence for safe and effective buprenorphine treatment, even for those using stronger opioids like fentanyl.
Researchers found that receipt of opioid use disorder-related telehealth services was associated with reduced risk for fatal drug overdoses. Additionally, medication from opioid treatment programs and buprenorphine in office-based settings also showed a protective effect.
A phase 3 randomised controlled trial found monthly injections of fitusiran effective in reducing bleeds in patients with severe haemophilia A or B. The study included 56 male patients with inhibitors, who experienced no bleeds after nine months on prophylactic treatment.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
A global research team found that long-term methylphenidate treatment does not increase the risk of growth impairments or psychiatric events, but may lead to modest increases in blood pressure. The study suggests potential disparities in ADHD medication access by country-income levels.
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
Receiving buprenorphine after a nonfatal opioid overdose significantly lowers the risk of subsequent overdose death. The medication was associated with a 62% reduction in risk, highlighting the need for lifesaving treatment following these events. Current evidence shows low uptake of buprenorphine and other medication-assisted treatments.
The Octapharma USA grant supports the Immunoglobulin National Society's breakfast symposium on PANS/PANDAS, a subset of pediatric acute-onset neuropsychiatric syndrome associated with strep. The program will focus on diagnosis criteria, pathogenic mechanisms, and current treatment options for challenging cases.
Corneal graft rejection can be as high as 10% due to poor patient compliance with medications, which require frequent eyedrop administrations. Researchers at Virginia Commonwealth University developed nanoparticles to encapsulate eye medication, decreasing graft rejection while requiring fewer and smaller doses. The approach reversed s...
Researchers at Tel Aviv University found that dedicated hyperbaric oxygen therapy is more effective in reducing pain and healing patients with fibromyalgia caused by traumatic brain injury. The treatment resulted in significant improvements in 2 out of 5 patients, including improved pain threshold tests and quality of life indicators.
A study found that people with epilepsy have a higher risk of early death, especially in younger individuals, those taking multiple medications, and those living in rural areas. The increased risk varies depending on the individual's specific circumstances.
The new medicine has shown promising results in a Phase 1 clinical trial, with 70% of patients stable after six weeks and one patient remaining stable for over two years. Developed by NTNU researcher Marit Otterlei, ATX-101 targets cancer cells' stress regulation system, leaving healthy cells unaffected.
A pilot study found that patients who listened to their favorite music experienced reduced nausea severity and distress. Music was believed to affect serotonin levels, a neurotransmitter associated with chemotherapy-induced nausea, in a way that could complement medication.
Researchers have discovered a novel medication that effectively treats a rare hereditary muscle disease causing complete immobility and death. The treatment has also shown promise in treating severe statin-associated myopathy, with improved symptoms in patients awaiting treatment.
Cases of Candida auris, a highly contagious fungal infection, rose drastically between 2019 and 2021, with an increase in echinocandin-resistant cases. The findings emphasize the need for improved detection and infection control practices to prevent the spread of C auris.
A new study reveals that the SPUR tool, developed by Kingston University and Observia, can accurately predict hospital admissions and early readmissions in people with Type 2 Diabetes. The tool has been found to be effective in reducing hospital admissions and improving patient outcomes.
Researchers at the Salk Institute discovered that combining two therapeutic drugs, entinostat and trametinib, can significantly reduce tumor volume and number in mice with LKB1-mutated non-small cell lung cancer. The findings could lead to clinical trials in humans and potentially transform treatment for cancers beyond NSCLC.
Experts advocate for genetic testing to identify MS patients at high risk of developing progressive multifocal leukoencephalopathy (PML), a devastating side effect from medications. The availability of such testing could allow physicians to use alternative therapies, reducing the risk of PML.
A new study published in the New England Journal of Medicine found that lebrikizumab was effective in treating moderate to severe atopic dermatitis, improving skin clarity and reducing itching. The study involved two phase 3 trials with over 700 participants and showed promising results for the treatment.
A multicenter study found that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years while maintaining previously achieved clinical improvement. This breakthrough therapy has improved the quality and length of patients' lives, with some even seeing a 15% increase in lung function.
A new study found that bupropion, an antidepressant medication, can help people stop using cocaine while receiving methadone for opioid use disorder. Participants who received monetary incentives to quit cocaine saw a higher success rate when taking bupropion compared to those with placebo.
A new study published in The Lancet found that an existing drug, sulfadoxine-pyrimethamine, protects pregnant women from sexually transmitted and reproductive tract infections. Researchers tested this drug alongside a promising new treatment, dihydroartemisinin-piperaquine, which showed unique ability to prevent malaria.
Researchers from China conducted a comprehensive review of dual therapy (DT) for H. pylori eradication, highlighting its high efficacy and patient compliance with minimal adverse events. High-dose DT administered over 14 days has emerged as the most effective treatment option.
A study by University of Georgia researchers found that revised prescription labels with explicit instructions can dramatically improve medication adherence to antihypertension medications, contraceptives, and asthma controllers. This improvement was seen in patients taking these medications, including those with asthma, hypertension, ...
Recent review article discusses clinical development in long-acting growth hormone (LAGH) therapy, which mimics natural GH release patterns. LAGH therapies reduce daily injection burden, improving patient compliance and treatment outcomes.
A phase two trial found that exenatide significantly reduced brain pressure and monthly headaches in seven patients with Idiopathic Intercranial Hypertension (IIH). The study showed a rapid action of the drug, with results indicating significant reductions in brain pressure and headache days compared to the placebo arm.
The magrolimab plus azacitidine regimen resulted in a complete response rate of 33% and partial response rate of 75%. Patients with TP53 mutations showed improved overall survival rates compared to previous studies.
Researchers at Brigham and Women's Hospital tested a new nasal monoclonal antibody treatment, Foralumab, which decreased inflammatory markers and lung inflammation in patients with COVID-19. The treatment also showed similar effects in multiple sclerosis patients, suggesting its potential use for treating other diseases.
A new study reveals that military members with mild traumatic brain injury (mTBI) who identify as 'Other' are at a significantly higher risk of suicide and overdose deaths. The study found that the rates of these deaths were highest among members of this group, despite making up only 7.38% of the study sample.
A new study published in Arthritis & Rheumatology reports significant improvements in disease activity for patients with refractory juvenile dermatomyositis treated with abatacept therapy. The randomized controlled trial demonstrates the potential of abatacept as a treatment option for this rare and debilitating condition.